Around one in four adults in Britain is obese, costing the public health care system billions annually; the government sees weight-loss injections as a solution.
The government announced a £279 million investment from Eli Lilly to explore new health service delivery methods for obesity and conduct a five-year trial of tirzepatide.
The trial will assess tirzepatide's effectiveness in weight loss, diabetes prevention, and evaluating employment status and sick days among participants according to the Health Innovation Network.
Prime Minister Keir Starmer emphasized that weight-loss drugs like tirzepatide are essential for health and the economy, crucial for helping people return to work.
Collection
[
|
...
]